TrialJAMA network open2023

Effect of Rivaroxaban vs Enoxaparin on Major Cardiac Adverse Events and Bleeding Risk in the Acute Phase of Acute Coronary Syndrome: The H-REPLACE Randomized Equivalence and Noninferiority Trial.

Shenghua Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.